Retatrutide is an investigational “triple agonist” designed to activate three metabolic receptors at once: GLP-1, GIP, and glucagon. This multi-pathway approach aims to regulate metabolism more powerfully than single- or dual-action compounds. In early research, Retatrutide has shown some of the strongest weight-loss results to date, along with improvements in blood sugar, liver fat, and overall metabolic health.
Key information and effects
- Retatrutide has shown significant weight-loss potential in clinical trials, producing greater reductions in body weight than current GLP-1-only medications.
- By activating GLP-1 and GIP receptors, it enhances insulin secretion, reduces appetite, slows gastric emptying, and improves blood glucose control.
- Activation of the glucagon receptor increases energy expenditure and may help reduce liver fat.
- Early studies indicate benefits for people with obesity, type 2 diabetes, and metabolic-associated fatty liver disease.
- Participants in trials have seen improvements in cholesterol, inflammation markers, and overall metabolic health.
Disclaimer: This product is for laboratory research purposes only. Not for human or animal consumption. Cap colour subject to change.
Certificate of Analysis
Reviews
There are no reviews yet.